Changes included: - Moved immunogenicity endpoint to secondary objectives. - Increased the screening period from 28 days (4 weeks) to 48 days. - Removed the reference to the Patient Global Assessment (PGA) of disease activity and replaced with Patient Assessment of Palmoplantar Pustulosis Disease Activity. - Increased the number of study centers from 10 to 25. - Increased the upper age limit of subjects from 70 years to 75 years. - Inclusion Criteria, criterion 3, revised to remove reference to lack of response to prior topical or corticosteroid therapy. - Added a caveat that out-of-range screening values may be assessed by the Investigator and subjects may be enrolled at the discretion of the Investigator following consultation with the Medical Monitor and Sponsor. Removed the clause allowing one repeat test for abnormal laboratory results. - Exclusion Criteria, criterion 13 revised to allow squamous cell carcinoma as determined by the Investigator to be fully treatable. - Added a criterion to exclude subjects for inability to tolerate SC drug administration. - Clarified the appearance description of ANB019 and placebo. - Added a paragraph to describe the study procedures for early withdrawal. - Added an additional urine pregnancy text collection at the Week 20 study visit. - For FSH collection, removed the criteria in the definition of postmenopausal that stated women must be 45 years of age. - Added the endpoint for ADA assessment.

Changes included: - Revised the duration allowed for previous chest x-ray from 6 months to 12 months. - Removed the following sentence: “If any laboratory results are outside the upper or lower limits listed above, final determination of eligibility will be after Investigator assessment following consultation with the Medical Monitor and Sponsor. - Administrative changes for consistency with other AnaptysBio protocols.

Changes included: - Removed Week 4 from the primary analysis of PPASI50. - Revised text describing primary efficacy analysis with respect to analysis factors and use of 2-sided exact 95% test for the analysis of treatment differences. - Revised the wording of the exclusion criteria to permit enrollment of subjects with localized oral and genital herpes simplex that is well controlled. - Revised description of logistic regression model to identify factors used for analysis of 2 secondary efficacy endpoints (proportion of subjects achieving PPPASI50 and PPPASI75 at all study centers and proportion of patients with clear or almost clear assessment score on PPPIGA at all study center visits).

Changes included: - Updated Benefit/Risk Assessment to include ANB019-005 final TEAE results and 26-week toxicology study in cynomolgus monkeys

Changes included: - Changed the primary endpoint to mean change from Baseline in PPPASI at Week 16. Moved proportion of subjects achieving PPPASI50 at Week 16 from primary to secondary objective. - Changed description of statistical methods for analysis of primary efficacy endpoint. - Minor editorial changes for accuracy and formatting.